Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result
| Autor: | Lokman Irkilata, Mustafa Aydin, Hasan Riza Aydin, Hüseyin Cihan Demirel, Mustafa Kadihasanoglu, Mustafa Kemal Atilla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | International Neurourology Journal, Vol 19, Iss 2, Pp 85-89 (2015) |
| Druh dokumentu: | article |
| ISSN: | 2093-4777 2093-6931 |
| DOI: | 10.5213/inj.2015.19.2.85 |
| Popis: | Purpose: This study aimed to verify the efficacy and safety of intravesical treatment with sodium chondroitin sulfate (CS) in patients with overactive bladder (OAB) who are refractory to previous antimuscarinic treatment. Methods: This study was performed between June 2012 and January 2015 and included 31 consecutive women (mean age, 42.10±7.34 years) with OAB who had been previously treated with two types of antimuscarinic drugs. The results of gynecologic and cystoscopic examinations were normal, and OAB comorbidity was absent. Treatment with intravesical instillations containing 40 mL CS (0.2%; 2 mg/mL) was administered for 6 weeks; after weekly treatments, monthly treatments were administered. The OAB-validated 8 (OAB-V8) symptom scores, nocturia, frequency, urgency, urge incontinence, and urinary volumes measured by uroflowmetry were evaluated for all the patients. The values obtained before the treatment were statistically compared with those obtained six months after the treatment. Results: The duration of the symptoms was 18.36±6.19 months. A statistically significant improvement of the patients’ conditions was observed in terms of the OAB-V8 symptom scores, nocturia, frequency, urgency, urge incontinence, and urinary volumes measured by uroflowmetry after the treatment. Conclusions: Despite the limitations of this study, the outcomes confirmed that CS therapy is safe and effective for the treatment of OAB. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|